AbCellera (ABCL) Stock
Key stats
- Market cap
- $3.90B
- Price / Earnings ratio
- -27.4x
- EPS (TTM)
- -$0.48
- Volume
- Loading
- 52-week high
- $15.02
- 52-week low
- $2.75
- EPS vs analyst estimate
- -11.8%Q3 FY25 · -$0.19 vs -$0.17
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with ABCL
Recent news
AbCellera to Present at Upcoming Investor Conferences in November 2026
AbCellera to Present at Upcoming Investor Conferences in November 2026
ABCL
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
ABCL
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
ABCL
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
ABCLNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.18
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.05
- MACD histogram
- -0.02
- SMA 50
- $12.33
- Price below SMA 50
- EMA 50
- $11.83
- Price above EMA 50
- SMA 200
- $7.16
- Price above SMA 200
- EMA 200
- $7.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.11 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
AbCellera to Present at Upcoming Investor Conferences in November 2026
AbCellera to Present at Upcoming Investor Conferences in November 2026
ABCLAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
ABCLWhy Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
ABCLABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
ABCL
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
ABCL
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
ABCL
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
ABCL
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
ABCL
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
ABCL
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
ABCLNews tone: automated (AI) classification of the article's content, not a price prediction.
About AbCellera
AbCellera grew out of the idea that single-cell microfluidics and next-generation technologies can radically change how we discover drugs. But this isn’t just about having advanced technology. It comes from building a world-class group of innovators. Our multidisciplinary team of cell biologists, biochemists, engineers, data scientists, machine learning experts, and business professionals is working on some of the toughest areas of disease. We push the limits of antibody discovery to help partners tackle the world’s most urgent medical challenges.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Carl L.G. Hansen Ph.D. | CEO, President & Chairperson | 1975 |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer | 1974 |
| Dr. Veronique Lecault Ph.D. | CTO & Director | 1985 |
| Mr. Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 1970 |
| Mr. Andrew Knowles M.Sc. | Vice President of Operations | — |
| Mr. Martin Hogan M.Sc. | Senior Director of Strategic Finance & IR | — |
| Ms. Tiffany Chiu B.Sc., Ph.D. | Vice President of Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.18
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.05
- MACD histogram
- -0.02
- SMA 50
- $12.33
- Price below SMA 50
- EMA 50
- $11.83
- Price above EMA 50
- SMA 200
- $7.16
- Price above SMA 200
- EMA 200
- $7.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.00
- Average
- $15.40
- High
- $18.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.7 | -1.9 | ||||||||||
| 2022 | -36.4 | -6.4 | +7.9 | -24.3 | -5.6 | +36.5 | -5.6 | +5.2 | -10.7 | +15.4 | +11.9 | -23.1 |
| 2023 | +11.0 | -21.9 | -7.5 | -9.4 | +3.0 | -4.9 | +17.3 | -25.0 | -17.7 | -7.8 | +14.3 | +18.2 |
| 2024 | -10.8 | -2.9 | -10.3 | -14.9 | +3.7 | -23.7 | +17.3 | -16.1 | +4.0 | +6.2 | +10.3 | -3.3 |
| 2025 | +4.6 | -15.9 | -5.5 | +24.9 | -18.9 | +60.3 | +28.1 | -1.4 | +24.2 | -6.9 | -30.5 | -1.4 |
| 2026 | +5.5 | +3.1 | -8.6 | +18.2 | +39.3 | +21.5 | -24.9 | +96.9 | +29.3 | -11.8 | +7.5 |
